Li Kang Biomedical Co Ltd (6242) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of Li Kang Biomedical Co Ltd stock TWD 25.25, price TWD 31.50, that is 19.8% below the price, quality 46 out of 100. Rating: overvalued. Calculated from audited financials with 14 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 3, 2026.
How to read this chart
60‑month range 24.47 TWD – 56.95 TWD · fair‑value band 23.23 TWD – 28.71 TWD · the 31.50 TWD price screens above the 25.25 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 3, 2026.
Follow Li Kang Biomedical Co in your weekly email
Every Wednesday you see whether Li Kang Biomedical Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Li Kang Biomedical Co., Ltd. manufactures and sells supplement, cosmeceutical, and hygienic drink products. It also engages in the management and consulting of tourism factory business; and offers telemarketing services.
Show moreShow less
The company was formerly known as BAFO Technologies Corporation and changed its name to Li Kang Biomedical Co., Ltd. in September 2014. Li Kang Biomedical Co., Ltd. was founded in 1982 and is based in Tainan City, Taiwan.
Stock analysis
Li Kang Biomedical Co Ltd (6242) currently trades at 31.50 TWD, while our model-based Fair Value estimate is 25.25 TWD, 20% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of 46.60 TWD per share, and 5 of the 14 models we run sit above the 31.50 TWD price.
Bear case: the Dividend Discount group reads lowest at 20.44 TWD, and 9 of the 14 models stay below the price. Data coverage for this calculation is low.
Scenario range: 23.23 TWD (bear) to 28.71 TWD (bull), the price of 31.50 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 46/100 (below-average quality), in the Consumer Cyclical sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Li Kang Biomedical Co Ltd reported revenue of 589M TWD in FY2025 versus 387M TWD in FY2021, a compound +11.1%/yr. Reported net income was 83.8M TWD in FY2025, compounding +13.0%/yr from FY2021.
Key figures
Market cap 1.0B TWD (≈ $30.5M) Micro · P/E ratio 13.2 · P/S ratio 1.75 · EPS (TTM) 2.39 TWD · Dividend yield 6.3% · Net margin 13.3% · Return on equity 9.1% · Return on assets (EBIT) 13.1% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 54 out of 100 (low confidence).
What moves the price
The share trades about 16% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Consumer Cyclical peers we cover trades at 10% fair-value upside, at −20%, 6242 screens richer than that median.
Fair Value models
Bear23.23 TWDFair Value 25.25 TWDBull28.71 TWD
Price 31.50 TWD · Downside -19.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (0.3344 TWD per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.36/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+4.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.2%
Start year 2020 (pandemic). Over 10 years: +2.6% a year
Revenue growth 23 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.0%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+7.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year+1.2%
Dividend (yield on the price)6.3%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.19% → 17%
⚠ Revenue per share shrinking 3.1%/yr over ~6Y (margins intact) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Compare Li Kang Biomedical Co Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Travel Services · 86 stocks
Beats the industry median on 8/12 measures
Overall it ranks above its industry peers.
Valuation
Quality Score46 · Bottom 25%
Fair Value upside−19.8% · Below median
Profitability
Return on equity (12 months)9.1% · Above median
Return on assets7.7% · Top 25%
Net margin (12 months)13.3% · Top 25%
Operating margin (12 months)16.7% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)−1.6% · Below median
Dividend yield (12 months)6.3% · Top 25%
Valuation Multiplesvs Travel Services median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Li Kang Biomedical Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/6242
Frequently asked questions
Is Li Kang Biomedical Co Ltd (6242) overvalued or undervalued?
As of Nov 3, 2026, our model estimates a fair value of 25.25 TWD versus a price of 31.50 TWD, about 20% lower (overvalued).
What is the fair value of 6242?
Our model-based fair value for Li Kang Biomedical Co Ltd is 25.25 TWD (as of Nov 3, 2026), built from audited fundamentals. The current price: 31.50 TWD.
What is the quality score of 6242?
Li Kang Biomedical Co Ltd has a Quality Score of 46/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Li Kang Biomedical Co Ltd (6242)?
Our model-based price target is the fair value of 25.25 TWD (as of Nov 3, 2026) from 14 valuation models. Cautious scenario 23.23 TWD, optimistic scenario 28.71 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Li Kang Biomedical Co Ltd stock forecast for 2026?
Our models put fair value at 25.25 TWD, about 20% lower versus a price of 31.50 TWD (overvalued). Cautious scenario 23.23 TWD, optimistic scenario 28.71 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Li Kang Biomedical Co Ltd (6242)?
Li Kang Biomedical Co Ltd reported trailing-twelve-month revenue of about 573M TWD (latest available figure, as of Nov 3, 2026).
Does Li Kang Biomedical Co Ltd pay a dividend?
Li Kang Biomedical Co Ltd currently shows a dividend yield of 6.35% relative to its recent price (as of Nov 3, 2026).
How much is the dividend of Li Kang Biomedical Co Ltd (6242) and when is the ex-dividend date?
Li Kang Biomedical Co Ltd pays a dividend of 2.00 TWD per share a year, a dividend yield of 6.3%. The last ex-dividend date was Jun 16, 2026. A dividend has been paid every year since at least 2016. The payout ratio is 83.7% of earnings. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What is the intrinsic value of Li Kang Biomedical Co Ltd (6242)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Li Kang Biomedical Co Ltd it is 25.25 TWD per share (as of Nov 3, 2026), against a price of 31.50 TWD. It is the blended result of 14 valuation models in 6 families (Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Li Kang Biomedical Co Ltd stock overvalued or undervalued in 2026?
As of Nov 3, 2026, 6242 trades above its calculated fair value: price 31.50 TWD, fair value 25.25 TWD, a gap of about −20% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6242?
No. The price is what the market pays today (31.50 TWD); the fair value is what the company's own numbers justify (25.25 TWD). For Li Kang Biomedical Co Ltd the two are 6.25 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Li Kang Biomedical Co Ltd worth?
The market values Li Kang Biomedical Co Ltd at about 1.0B TWD (market capitalisation, as of Nov 3, 2026). Per share that is 31.50 TWD; our models calculate a fair value of 25.25 TWD per share.
What do the bullish and bearish scenarios say about 6242?
Our models span a range for Li Kang Biomedical Co Ltd: cautious scenario 23.23 TWD, base 25.25 TWD, optimistic 28.71 TWD per share (as of Nov 3, 2026, price 31.50 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 6242?
Li Kang Biomedical Co Ltd trades at a price-to-earnings ratio of 13.2 (as of Nov 3, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 25.25 TWD is built from several models across several years. Other multiples: P/B 1.2, P/S 1.7, EV/EBITDA 10.2.
How solid is the balance sheet of Li Kang Biomedical Co Ltd (6242)?
Balance-sheet figures for Li Kang Biomedical Co Ltd (as of Nov 3, 2026): return on equity 9.1%. They feed the Quality Score of 46/100, which measures business quality independently of the share price.
How far is 6242 from its 52-week high?
Li Kang Biomedical Co Ltd trades at 31.50 TWD, about 16% below its 52-week high of 37.71 TWD and at the low of 31.50 TWD (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 25.25 TWD is for.
Which stocks are comparable to Li Kang Biomedical Co Ltd?
From the same area (Consumer Cyclical) we also value Booking Holdings, Airbnb, Inc, Royal Caribbean Cruises Ltd, Viking Holdings, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Li Kang Biomedical Co Ltd stock attractive at the current price?
The data as of Nov 3, 2026: price 31.50 TWD, calculated fair value 25.25 TWD (−20%), Quality Score 46/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6242 calculated?
We run Li Kang Biomedical Co Ltd through 14 models from 6 families: Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 25.25 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Li Kang Biomedical Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Li Kang Biomedical Co Ltd (6242)?
The closing price on Nov 9, 2026 was 31.50 TWD. Our model-based fair value is 25.25 TWD, about 20% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Li Kang Biomedical Co Ltd right now?
The price sits above even our optimistic bull case (28.71 TWD). The favourable scenario is already priced in. Weak quality (46/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Li Kang Biomedical Co Ltd
How large is the market capitalisation of Li Kang Biomedical Co Ltd (6242)?
The market capitalisation of Li Kang Biomedical Co Ltd is 1.0B TWD (≈ $30.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Li Kang Biomedical Co Ltd (6242)?
The price-to-sales ratio of Li Kang Biomedical Co Ltd is 1.75 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Li Kang Biomedical Co Ltd (6242)?
Earnings per share at Li Kang Biomedical Co Ltd are 2.39 TWD (price ÷ EPS = P/E 13.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Li Kang Biomedical Co Ltd (6242)?
The dividend yield of Li Kang Biomedical Co Ltd is 6.3% (payout 83.7%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Li Kang Biomedical Co Ltd (6242)?
The net margin of Li Kang Biomedical Co Ltd is 13.3% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Li Kang Biomedical Co Ltd (6242)?
The return on equity (ROE) of Li Kang Biomedical Co Ltd is 9.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Li Kang Biomedical Co Ltd (6242)?
On an EBIT basis the return on assets of Li Kang Biomedical Co Ltd is 13.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Li Kang Biomedical Co Ltd (6242)?
The operating margin of Li Kang Biomedical Co Ltd is 16.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Li Kang Biomedical Co Ltd (6242)?
Revenue at Li Kang Biomedical Co Ltd is growing −1.6% versus a year earlier (3y avg −4.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Li Kang Biomedical Co Ltd (6242)?
Earnings per share at Li Kang Biomedical Co Ltd are growing −4.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Li Kang Biomedical Co Ltd (6242) generate?
The free cash flow of Li Kang Biomedical Co Ltd is −237M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Li Kang Biomedical Co Ltd (6242) carry?
The net debt of Li Kang Biomedical Co Ltd is 49.4M TWD (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Li Kang Biomedical Co Ltd in the live analysis
One click puts Li Kang Biomedical Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 3, 2026